Open AccessTeriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis
Author(s) -
Vanessa F Moreira Ferreira,
Danielle Caefer,
Natalie Erlich-Malona,
Brian Healy,
Tanuja Chitnis,
James Stankiewicz
Publication year - 2020
Publication title -
multiple sclerosis international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 6
eISSN - 2090-2662
pISSN - 2090-2654
DOI - 10.1155/2020/5471987
Subject(s) - glatiramer acetate , medicine , teriflunomide , expanded disability status scale , hazard ratio , multiple sclerosis , tolerability , population , confidence interval , proportional hazards model , physical therapy , adverse effect , disease , fingolimod , immunology , environmental health
Objectives To explore the safety and efficacy profile of teriflunomide in progressive multiple sclerosis.Methods We conducted a single-center retrospective observational analysis of a progressive multiple sclerosis population, assessing safety and efficacy in patients treated at least one year with teriflunomide or glatiramer acetate. Sustained progression of expanded disability status scale and sustained worsening of timed 25-foot walk were compared using a Cox proportional hazards model.Results Teriflunomide group ( n = 29) mean characteristics: age = 58 years (SD ± 7.6), disease duration = 16.7 years (SD ± 9.5), expanded disability status score = 5.9 (SD ± 1.3), and follow − up = 32.4 months (SD ± 13.6). Glatiramer acetate group ( n = 30) mean characteristics: age = 52.4 years (SD ± 11.3), disease duration = 15.1 years (SD ± 10.4), expanded disability status score = 5.7 (SD ± 1.6), and follow − up = 46.9 months (SD ± 43.9). Both treatments were well tolerated without serious side effects. After adjustment for age, sex, and baseline expanded disability status score, sustained expanded disability status score progression did not differ between groups (hazard ratio = 1.17; 95% confidence interval: 0.45, 3.08; p = 0.75). Sustained timed 25-foot walk worsening after adjustment also did not differ (hazard ratio = 0.56; 95% confidence interval: 0.2, 1.53; p = 0.26).Conclusion In an advanced progressive multiple sclerosis population, no substantial differences in tolerability, safety, sustained EDSS progression, or sustained T25FW worsening over time were observed between glatiramer acetate and teriflunomide-treated groups. The small sample precluded definitive determination.